Skip to main content
Clinical Trials/JPRN-jRCT2080225290
JPRN-jRCT2080225290
Completed
Phase 1

A Phase I, Open label, Multi-Center Clinical Pharmacological Study of nemolizumab with a Single-dose in Japanese Atopic Dermatitis Patients with moderate to severe pruritus

Maruho Co., Ltd.0 sites25 target enrollmentJuly 22, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Atopic dermatitis with pruritus who are inadequately controlled by existing therapies
Sponsor
Maruho Co., Ltd.
Enrollment
25
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 22, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Atopic dermatitis with moderate or severe pururitus Patients

Exclusion Criteria

  • \-Patients with Hepatitis B virus or hepatitis C virus infection
  • \-Patients with Evidence of tuberculosis (TB) infection
  • \-Patients with immune deficiency
  • \-Pregnant or lactating women

Outcomes

Primary Outcomes

Not specified

Similar Trials